Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 7Prostatic Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Neuroectodermal Tumors, Primitive 2Hypoxia 2Neuroendocrine Tumors 1Neoplasm Metastasis 1Melanoma 1Liver Neoplasms 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 4lanreotide 4Sunitinib 4Temozolomide 3Octreotide 3Nivolumab 3Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3Capecitabine 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3copper dotatate CU-64 2amino-acid, glucose, and electrolyte solution 2Quality of Life 2FAPI-46 2veliparib 1tivozanib 1tislelizumab 1telotristat ethyl 1surufatinib 1romidepsin 1repotrectinib 1pralsetinib 1pembrolizumab 1pasireotide 1gallium Ga 68 dotatate 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × TH 302 × Gastrointestinal × Clear all
NCT02402062 2020-07-27

A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
17 enrolled 55 charts
EndocrineGastrointestinalNET

Pancreatic Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡